I would like to share all audiences. It is time to face scientific truth: " Life Science = BioMedicine + BioTechnology, in terms of life science itself. BioMedicine is the core software, BioTechnology is the hardware. Without success of BioMedicine, BioTechnology would be useless; Without biomedicine as a key, life science research fail into right way " . This is, Dr. Shiue, Motto which is our US BioMedicine inside speaking in 1990. Therefore, in this 21th century, we hope to have opportunity to demonstrate Bill Gates eye is wrong, because he say: " He is now the world's richest, who is BT (BioTechnology) will have a chance to transcend him in the future, if any " . However, I say this one is BM (BioMedicine) and not BT.
When the global runs crazy after the BT investment, senior Tsumura & Co. coped out on chasing FDA approvals before it attains the achievement; ImClone Systems (IMCL:) basically failed to bet their boots on " research IMC-225 (now called Erbitux) as cancer medication to block the activation of EGFR (Epidermal Growth Factor Receptor) " , for over 20 years, being led research by Dr. John Mendelsohn who is the cancer drug pioneer and first student studying in the laboratory at Harvard University of Nobel laureate Dr. James Watson. The boss of Erbitux Samuel Waksal was arrested for attempting illegal sells share of ImClone stock on insider-trading charges on 12/27/2001 after they muscle in FDA application. It is just one day before the FDA negative Erbitux, 12/28/2001. The ImClone shares plummeted over 85% on the same day.
BT achiever Dr. Craig Venter make Celera Genomics sequence the entire human genome just mere $0.3 billion ($300 million)+an $80 million supercomputer in a mere 3 years from May 1998 successfully beat NIH which the U.S. government approved a 15-years for $3 billion plan from 1990 to launch the HGP (Human Genome Project) at the helm of the project was Dr. James Watson, Nobel Prize-Winning for discovery of the double helix structure of DNA in 1953. However, when Craig Venter step down as president/CEO of Celera Genomics on 23rd Jan. 2002, as Celera decides re-organize as a pharmaceutical business and drug discovery company, by now he headlong find his vital failure is exactly to reckon without PDBM: " Profit-driven Business Model " . However, I doubt who will be able to clearly understand that PDBM in BT is totally relying on BM research completion and widely innovative application in human healthcare and disease solution.